Skip to content

Raphael Pharmaceutical Inc.

RAPH

CIK 0001415397

← back to feed
Revenue (TTM)
—
Q1 May 2026
Net Income (TTM)
−$1.24M
+15.8% YoY Q1 May 2026
EPS Diluted (TTM)
$0.06
−12.5% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
—
Q1 May 2026
Net Margin
—
Q1 May 2026
Free Cash Flow (TTM)
−$826K
Q1 May 2026
Cash
$20K
Q1 May 2026
Total Debt
$150K
Q1 May 2026
Shares Outstanding
20.18M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings